<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Exhibit
99.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt">Beyond
Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase
1b Clinical Trial Utilizing Low Volume Ultra-High Concentration
Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt">-
<I>The Phase 1b study will evaluate LV UNO in unresectable cutaneous or
subcutaneous histologically confirmed primary or metastatic solid
tumor cancer patients that have progressed or have prolonged stable disease on
single agent PD-1 inhibitors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt">-
<I>The primary objective of the Phase 1b study is to assess preliminary efficacy
by objective response rate (ORR) and duration of response
(DOR) per RECIST version 1.1 and secondarily immune-related response via
iRECIST</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt">-
<I>The study will recruit patients from four sites across Israel</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;
margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>HAMILTON,
BERMUDA, December 3, 2024 <I>&ndash;</I></B> Beyond Cancer, Ltd., a
clinical-stage biotechnology company developing ultra-high concentration
nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced
that the Israeli Ministry of Health (IMOH) has approved
the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial of LV UNO in
combination with anti-PD-1 therapy. The trial will be conducted
at four sites in Israel and patient screening will begin in the first quarter of
2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">The
Phase 1b trial (NCT05351502) is a clinical proof-of-concept trial that will
assess the intratumoral administration of LV UNO in patients
with unresectable cutaneous or subcutaneous histologically confirmed primary or
metastatic lesions, who have shown disease progression
or prolonged stable disease (&ge; 12 weeks) after receiving a single agent
anti-PD-1 containing treatment. The trial, which is expected
to enroll up to 20 subjects, is designed to assess the preliminary efficacy of
LV UNO by objective response rate (ORR) and duration of
response (DOR) per RECIST v1.1 and secondarily immune-related response via
iRECIST. Safety and tolerability of LV UNO in combination
with anti-PD-1 therapy, as well as its potential to enhance the type, density,
and distribution of immune cells within the tumor microenvironment
will also be observed. Topline data from the Phase 1b portion of the study are
anticipated in the second half of 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&ldquo;We
are excited to initiate the Phase 1b trial of LV UNO, a potentially
groundbreaking solid tumor treatment approach, in combination with
PD-1 inhibitors,&rdquo; said Dr. Jedidiah Monson, Chief Medical Officer of
Beyond Cancer. &ldquo;In preclinical studies, a single dose
of UNO has been shown to increase PD-L1 expression and improve overall survival
in animal models compared to anti-PD-1 alone. Further,
Phase 1a human data that demonstrated immune system activation were presented at
ASCO&rsquo;s Key Opinion Leader Event held in June 2024.
We look forward to the Phase 1b trial results to establish the basis of further
investigation of UNO in combination with PD-1 inhibitors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&ldquo;The
initiation of the Phase 1b trial represents a major step forward in our vision
for personalized cancer treatment. We see UNO as a complementary
therapy for future cancer treatment paradigms, particularly for patients with
anti-PD-1 refractory or resistant disease, potentially
offering more patients access to effective treatment,&rdquo; stated Dr. Selena
Chaisson, Chief Executive Officer, and Director of Beyond
Cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt
solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse;
width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align:
left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P
STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>About
Nitric Oxide</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Nitric
Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven
to play a critical role in a broad array of biological
functions. In the airways, NO targets the vascular smooth muscle cells that
surround the small resistance arteries in the lungs. Currently,
exogenous inhaled NO is used in adult respiratory distress syndrome, post
certain cardiac surgeries and persistent pulmonary hypertension
of the newborn to treat hypoxemia. Additionally, NO is believed to play a key
role in the innate immune system and <I>in vitro</I> studies
suggest that NO possesses anti-microbial activity not only against common
bacteria, including both gram-positive and gram-negative, but
also against other diverse pathogens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>About
UNO Therapy for Solid Tumors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Cancer
is the second leading cause of death globally, with tumor metastases responsible
for approximately 90% of all cancer-related deaths.
Current cancer treatment modalities generally include chemotherapy,
immunotherapy, radiation, and/or surgery. Ultra-high concentration
Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or
metastatic disease. <I>In vitro</I> murine data show
that local tumor ablation with UNO stimulates an anti-tumor immune response in
solid tumor cancer models. Beyond Cancer, Ltd. believes
that UNO has the potential to prevent relapse or metastatic disease with as
little as a single 5-minute treatment and with limited toxicity
or off-target effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>About
Beyond Cancer, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Beyond
Cancer, Ltd. is a development-stage biopharmaceutical and medical device company
utilizing ultra-high concentration nitric oxide (UNO)
via a proprietary delivery platform to treat primary tumors and prevent
metastatic disease. Nitric oxide at ultra-high concentrations
has been reported to show anticancer properties and to potentially serve as a
chemosensitizer and radiotherapy enhancer. A first-in-human
study is underway in patients with solid tumors. Beyond Cancer is also
conducting preclinical studies of UNO in multiple solid tumor
models to inform additional treatment protocols. For more information, visit
<U>www.beyondcancer.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><I>This
press release contains &ldquo;forward-looking statements&rdquo; concerning the
potential safety and efficacy of inhaled nitric oxide
and the ultra-high concentration nitric oxide product candidate, as well as its
therapeutic potential in a number of indications; and
the potential impact on patients and anticipated benefits associated with
inhaled nitric oxide and the ultra-high concentration nitric
oxide product candidate. Forward-looking statements include statements about
expectations, beliefs, or intentions regarding product offerings,
business, results of operations, strategies or prospects. You can identify such
forward-looking statements by the words &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes&rdquo;
&ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;looks forward,&rdquo;
&ldquo;projects,&rdquo; &ldquo;goal,&rdquo; &ldquo;assumes,&rdquo;
&ldquo;targets&rdquo; and similar expressions and/or the use of future
tense or conditional constructions (such as &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;should&rdquo; and the
like) and by the fact that these statements do not relate strictly to historical
or current matters. Rather, forward-looking statements
relate to anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently
subject to risks and uncertainties that could cause actual
results to differ materially from any future results expressed or implied by the
forward-looking statements. These forward-looking statements
are only predictions and reflect views as of the date they are made with respect
to future events and financial performance. Many factors
could cause actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including risks related to the ability to raise additional capital; the timing
and results of future pre-clinical studies and clinical
trials concerning the ultra-high concentration nitric oxide product candidate;
the potential that regulatory authorities, including the
FDA and comparable non-U.S. regulatory authorities, may not grant or may delay
approval for the ultra-high concentration nitric oxide
product candidate; the approach to discover and develop novel drugs, which is
unproven and may never lead to efficacious or marketable
products; obtaining, maintaining and protecting intellectual property utilized
by products; competition from others using similar technology
and others developing products for similar uses; dependence on collaborators;
and other risks, which may, in part, be identified and
described in the &ldquo;Risk Factors&rdquo; section of Beyond Air, Inc.&rsquo;s
most recent Annual Report on Form 10-K and other of its
filings with the Securities and Exchange Commission, all of which are available
on Beyond Air, Inc.&rsquo;s website. Beyond Cancer and
Beyond Air undertake no obligation to update, and have no policy of updating or
revising, these forward-looking statements, except as
required by applicable law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>CONTACTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Corey
Davis, PhD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Cdavis@lifesciadvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">(212)
915-2577</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Matt
Johnson, Head of Corporate Development &amp; Strategy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Beyond
Cancer, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Mjohnson@beyondcancer.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><B>+++++++</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif;
font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT
STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt
solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse;
width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align:
left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT
STYLE="font-family: Times New Roman, Times, Serif; font-size:
10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
